Company Overview - Simulations Plus, Inc. provides software and consulting services to support drug discovery and development in the pharmaceutical industry [3]. Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Simulations Plus, stemming from allegations of providing misleading business information to investors [1]. - On April 15, 2025, Simulations Plus hired Grant Thornton as its auditor. Following weak preliminary Q3 results reported in June, the company's stock dropped over 24% to close at $20.05 per share [4]. - On July 14, 2025, Simulations Plus reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, despite the auditor's objections regarding unresolved reporting and internal control issues. This led to a further stock decline of 25.76%, closing at $12.97 per share [4].